Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model

PURPOSE: In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations. Additionally, a physiologically based pharmacokinetic (PBPK) model was created to assess such variatio...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Chemother Pharmacol
Egile Nagusiak: Gruber, Andrea, Czejka, Martin, Buchner, Philipp, Kitzmueller, Marie, Kirchbaumer Baroian, Nairi, Dittrich, Christian, Sahmanovic Hrgovcic, Azra
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2018
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5854746/
https://ncbi.nlm.nih.gov/pubmed/29453635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3545-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak